A Phase 1b Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of TAK-079 in Combination With Standard Background Therapy in Patients With Moderate to Severe Systemic Lupus Erythematosus
This Study is
No Longer Enrolling
Details
Age
Adult
Type of Study
Treatment
Locations
Barbara Davis Center
Study ID
Protocol Number: 19-0027
More information available at ClinicalTrials.gov: NCT03724916
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers